Equities

Evrofarma SA

EVROF:ATH

Evrofarma SA

Actions
  • Price (EUR)1.52
  • Today's Change0.000 / 0.00%
  • Shares traded400.00
  • 1 Year change+67.40%
  • Beta0.9152
Data delayed at least 20 minutes, as of Sep 19 2024 15:09 BST.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Financials data is unavailable for this security.

Balance sheet Back to Overview

In millions of EUR
(except for per share items)
Fiscal data as of Dec 31 2023202320222021
ASSETS
Cash And Short Term Investments0.661.440.25
Total Receivables, Net9.171214
Total Inventory6.195.252.75
Prepaid expenses------
Other current assets, total0.330.310.33
Total current assets161917
Property, plant & equipment, net302929
Goodwill, net------
Intangibles, net0.050.060.10
Long term investments0.660.710.69
Note receivable - long term0.330.030.03
Other long term assets0.000.00--
Total assets474947
LIABILITIES
Accounts payable------
Accrued expenses------
Notes payable/short-term debt3.902.440.72
Current portion long-term debt/capital leases3.112.752.52
Other current liabilities, total0.400.110.00
Total current liabilities131310
Total long term debt131618
Total debt202121
Deferred income tax1.081.181.18
Minority interest------
Other liabilities, total4.504.744.48
Total liabilities313534
SHAREHOLDERS EQUITY
Common stock5.741212
Additional paid-in capital00.940.94
Retained earnings (accumulated deficit)101.06(0.36)
Treasury stock - common------
Unrealized gain (loss)------
Other equity, total0.00----
Total equity161413
Total liabilities & shareholders' equity474947
Total common shares outstanding141414
Treasury shares - common primary issue000
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.